EVE Health Group Limited (AU:EVE)
ASX:EVE
Want to see AU:EVE full AI Analyst Report?
Top Page
EVE Health Group Limited
(Sydney:EVE)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.03
▲(40.00% Upside)
Action:ReiteratedDate:11/18/25
EVE Health Group Limited's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and profitability issues. Technical analysis indicates bearish trends, and valuation metrics are unattractive due to negative earnings. The absence of earnings call insights and corporate events further limits the score.
Positive Factors
Conservative capital structure
Very low leverage (debt/equity ~0.03) provides durable financial flexibility: lower refinancing and interest risk, capacity to fund operations or strategic moves from equity, and a stronger buffer through downturns. This structural conservatism supports survival and optionality over months.
Negative Factors
Declining revenue
Material revenue contraction (reported ~-32% in the dataset) is a structural concern: shrinking top line reduces scale, limits margin recovery, and constrains ability to invest in growth or absorb fixed costs. Persistent top-line decline over months can erode market position and strategic options.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative capital structure
Very low leverage (debt/equity ~0.03) provides durable financial flexibility: lower refinancing and interest risk, capacity to fund operations or strategic moves from equity, and a stronger buffer through downturns. This structural conservatism supports survival and optionality over months.
Read all positive factors
EVE Health Group Limited (EVE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$10.22M
Dividend YieldN/A
Average Volume (3M)774.07K
Price to Earnings (P/E)―
Beta (1Y)0.46
Revenue Growth-32.09%
EPS Growth34.85%
CountryAU
Employees3
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)-0.01
Shares Outstanding349,576,600
10 Day Avg. Volume491,958
30 Day Avg. Volume774,070
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.22
Price to Sales (P/S)2.49
P/FCF Ratio-2.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
EVE Health Group Limited Business Overview & Revenue Model
Company Description
Eve Health Group Limited, together with its subsidiaries, engages in the production and distribution of nutrition, health, and wellness products in Australia, New Zealand, the Asia Pacific, and North America. It provides organic tea tree oils; and...
How the Company Makes Money
null...
EVE Health Group Limited Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.36M | 1.73M | 2.13M | 2.33M | 2.01M | 2.80M |
| Gross Profit | 385.07K | 824.03K | 876.96K | 827.83K | -1.00M | -713.50K |
| EBITDA | -1.65M | -1.43M | -1.51M | -2.18M | -4.53M | -2.79M |
| Net Income | -1.62M | -1.58M | -1.90M | -4.04M | -5.37M | -3.63M |
Balance Sheet | ||||||
| Total Assets | 4.07M | 4.12M | 2.52M | 4.13M | 8.07M | 11.92M |
| Cash, Cash Equivalents and Short-Term Investments | 929.66K | 903.42K | 106.17K | 192.48K | 1.10M | 3.16M |
| Total Debt | 38.51K | 91.28K | 74.85K | 4.28K | 492.39K | 1.01M |
| Total Liabilities | 307.63K | 572.45K | 1.30M | 1.01M | 1.14M | 1.74M |
| Stockholders Equity | 3.76M | 3.55M | 1.22M | 3.12M | 6.93M | 10.19M |
Cash Flow | ||||||
| Free Cash Flow | -1.54M | -1.62M | -1.11M | -1.65M | -3.80M | -2.51M |
| Operating Cash Flow | -1.54M | -1.62M | -1.11M | -1.65M | -3.77M | -2.24M |
| Investing Cash Flow | 302.79K | 2.13M | 874.27K | 498.46K | -26.05K | -263.38K |
| Financing Cash Flow | 1.78M | 279.09K | 146.37K | 240.69K | 1.74M | 529.43K |
EVE Health Group Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
44 Neutral | AU$10.56M | -1.73 | -322.76% | ― | 12.52% | 52.17% | |
44 Neutral | AU$23.91M | -12.65 | -321.20% | ― | 2.96% | -866.67% | |
44 Neutral | AU$6.62M | -3.85 | -35.12% | ― | 96.60% | 67.50% | |
42 Neutral | AU$8.33M | >-0.01 | 226.76% | ― | -32.83% | 83.37% | |
41 Neutral | AU$10.22M | -1.62 | -44.35% | ― | -32.09% | 34.85% |
* Consumer Defensive Sector Average
AU:EVE
EVE Health Group Limited
0.03
>-0.01
-3.33%
AU:CCO
Fiji Kava Limited
―
―
―
AU:HCT
Holista Colltech Limited
0.07
0.02
51.16%
AU:NGS
Nutritional Growth Solutions Ltd.
0.03
<0.01
8.70%
AU:OMG
Forbidden Foods Ltd
0.01
-0.01
-50.00%
EVE Health Group Limited Corporate Events
EVE Health Group Issues 135.4 Million Unquoted Options for Future Capital Flexibility
May 8, 2026
EVE Health Group Limited has issued a substantial tranche of unquoted options as part of its capital management strategy, creating two new classes of securities. The company has granted 130.4 million options exercisable at AUD 0.04 expiring on 30 ...
EVE Health Director Boosts Indirect Stake via Share Placement
May 8, 2026
EVE Health Group Limited has reported a change in the holdings of director Stuart Gunzburg, who increased his indirect stake through entities associated with his family and investment vehicles. The update, lodged under ASX listing rule 3.19A.2, re...
EVE Health Group Seeks Quotation for 2.75 Million New Shares
May 8, 2026
EVE Health Group Limited has applied for quotation on the ASX of 2,750,000 ordinary fully paid shares, with the securities to be issued on May 8, 2026. The new share quotation, which follows a previously announced transaction, will modestly expand...
EVE Health Shareholders Back Capital Resolutions at General Meeting
May 8, 2026
EVE Health Group reported that all resolutions put to shareholders at its 8 May 2026 General Meeting were passed by poll, signalling strong investor support for recent capital initiatives and board-endorsed measures. The approved resolutions inclu...
EVE Health launches Libbo in Australia and broadens reformulated drug pipeline
Apr 28, 2026
EVE Health Group has begun the commercial launch of Libbo, its oral dissolving film treatment for erectile dysfunction, in Australia, supported by the new men’s health platform stiffissue.com that integrates digital education, telehealth pre...
EVE Health Group Names Ben Rohr CEO, Refines Leadership to Drive Product Commercialisation
Apr 27, 2026
EVE Health Group Limited has appointed former Chief Operating Officer Ben Rohr as Chief Executive Officer, effective immediately, highlighting the board’s push to accelerate commercialisation of its product portfolio and drive disciplined gr...
EVE Health Group Calls May 2026 General Meeting, Urges Proxy Voting
Apr 7, 2026
EVE Health Group Limited has called a general meeting of shareholders to be held on 8 May 2026 in Subiaco, Western Australia, outlining how investors can participate and vote. Shareholders are encouraged to lodge proxy forms in advance, underscori...
EVE Health Group Targets Capital-Light Scale With Reformulated Drug Delivery Platform
Mar 25, 2026
EVE Health Group is positioning itself as a reformulation specialist in pharmaceuticals and nutraceuticals, using proprietary delivery technology to enhance existing compounds and targeting scalable deployment through partners rather than direct s...
EVE Health Seeks ASX Quotation for 64.7 Million New Shares
Mar 22, 2026
EVE Health Group Limited has applied to the ASX for quotation of 64.7 million new fully paid ordinary shares, with an issue date of March 20, 2026. The move reflects a significant expansion of the company’s quoted capital base, which may inf...
EVE Health defines target market for options tied to capital raising
Mar 20, 2026
EVE Health Group Limited has outlined a target market determination for several series of options linked to a capital raising placement, including free attaching options for sophisticated investors, similar options for director Stuart Gunzburg, an...
EVE Health Group Launches $1.3m Placement and Options Prospectus
Mar 20, 2026
EVE Health Group Limited has released a transaction-specific prospectus outlining a capital raising via a placement of 64.7 million shares at $0.02 each, seeking $1.294 million, alongside associated options for placement subscribers and directors....
EVE Health Group Lifts Size of Planned Share Placement
Mar 18, 2026
EVE Health Group Limited has updated its proposed securities issue, notifying the ASX of an increase in the size of a planned placement first announced on 13 March 2026. The revised Appendix 3B filing reflects the larger capital raising plan, whic...
EVE Health Group Secures Cornerstone Investor, Lifts Placement to $1.3m
Mar 18, 2026
EVE Health Group has secured an additional $400,000 from a cornerstone investor in its latest placement, lifting total funds raised to about $1.3 million at $0.02 per share with free attaching options. The strategic investor brings pharmaceutical ...
EVE Health Group to Raise Capital via Share Placement and Large Option Issue
Mar 12, 2026
EVE Health Group Limited has announced a proposed capital raising via a placement, planning to issue 47,450,000 new ordinary fully paid shares on the ASX. The issuance is scheduled for 19 March 2026, indicating the company’s intention to str...
EVE Health Group Raises $0.9m to Drive Reformulated Drug Pipeline
Mar 12, 2026
EVE Health Group Limited has raised $904,000 via a placement to sophisticated and professional investors at $0.02 per share, with investors receiving free attaching options, to accelerate its reformulated pharmaceutical pipeline. The company is ta...
EVE Health Group Seeks Trading Halt Ahead of Capital Raising
Mar 10, 2026
EVE Health Group Limited has requested a trading halt on its securities on the ASX, effective 11 March 2026, while it considers, plans and executes a capital raising. Trading in EVE shares is expected to resume by the start of normal trading on 13...
EVE Health Expands Reformulated Drug Pipeline in Sexual Health and Cardiovascular Markets
Mar 9, 2026
EVE Health Group has completed research and development on several reformulated drug candidates in sexual health and cardiovascular therapy, using its proprietary delivery technologies to improve the performance of existing medicines. The expanded...
EVE Health bolsters scientific board as Libbo erectile dysfunction treatment rolls out
Mar 1, 2026
EVE Health Group has appointed specialist sexual health physician and general practitioner Dr Sama Balasubramanian to its Scientific Advisory Board, adding deep expertise in men’s health, sexual medicine, medical education and health governa...
EVE Health launches erectile dysfunction drug Libbo and integrated men’s digital health platform
Feb 9, 2026
EVE Health Group has launched Libbo, its oral dissolving film treatment for erectile dysfunction, in Australia and activated a dedicated men’s health digital platform, stiffissue.com. The company has partnered with telehealth providers hubMe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.